However, addition of IL-2 to elotuzumab in the co-cultures in the presence of either PBL (Fig. 6b) or purified NK cells (Fig. 6c) resulted in dose-dependent myeloma cell killing and NK cell activation as determined by CD25 and CD54 upregulation (data not shown). The gene discussed is IL2RA; the disease is plasma cell myeloma.